Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.61 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adamantane SCHEMBL3322185 | 0.99 | KMT2A (0.72) | KMT2AMEN1SMN1; SMN2RAB9ALMNA | |
| SCHEMBL3320032 | 0.86 | KMT2A (0.74) | KMT2AMEN1SMN1; SMN2RAB9ALMNA | |
| SCHEMBL3320998 | 0.81 | HPGD (0.75) | KMT2AMEN1LMNAEPHX2HSD11B1 | |
| SCHEMBL3322182 | 0.80 | LMNA (0.54) | KMT2AMEN1SMN1; SMN2RAB9ALMNA | |
| SCHEMBL2403178 | 0.80 | KMT2A (0.65) | KMT2AMEN1SMN1; SMN2RAB9AEPHX2 | |
| SCHEMBL2407868 | 0.78 | HDAC3 (0.71) | KMT2AMEN1SMN1; SMN2RAB9AEPHX2 | |
| SCHEMBL2403209 | 0.78 | HDAC3 (0.71) | KMT2AMEN1SMN1; SMN2RAB9AEPHX2 | |
| SCHEMBL14705918 | 0.76 | ALDH1A1 (0.54) | KMT2AMEN1SMN1; SMN2LMNAHSD11B1 | |
| SCHEMBL3322179 | 0.76 | LMNA (0.63) | KMT2AMEN1SMN1; SMN2RAB9ALMNA | |
| SCHEMBL14648365 | 0.74 | GPR55 (0.50) | KMT2AMEN1RAB9ALMNAHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120789-A1 | Compound | STERIX LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120789-A1 | Compound | STERIX LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | STERIX LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | STERIX LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| EP-1861384-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | Sterix Limited (GB) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006100502-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | STERIX LIMITED (GB) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | HSD3B1, HSD3B2, HSD11B1 | KMT2A 3083/4885MEN1 3474/4885SMN1; SMN2 4801/4885 |
| US-20100120789-A1 | Compound | NR0B2, NR0B1, NR4A1 | KMT2A 2533/4885MEN1 2608/4885SMN1; SMN2 4612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.